Ulcerative Colitis

New treatment option offered for patients with moderate ulcerative colitis

Published in Clinical Trials Week, November 29th, 2004

Results of a study presented by a Mayo Clinic physician at the 69th Annual Scientific Meeting of the American College of Gastroenterology (ACG) in Orlando, Florida, offer a new treatment option for patients who have moderately active ulcerative colitis.

William Sandborn, MD, Division of Gastroenterology and Hepatology. Mayo Clinic, Rochester, Minnesota, said if the treatment receives approval from the U.S. Food and Drug Administration (FDA), it will provide a new treatment for patients who need higher doses of the drug mesalamine, instead of resorting to steroid therapies, which sometimes have harsh side effects.

The study, sponsored by Procter &...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2004-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry